Meiwei Biopharmaceutical voluntarily disclosed the announcement on the inclusion of 9MW2821 for the indication of urothelial carcinoma into breakthrough therapy drugs.

SZSI · Aug 12

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.